Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBITDA Margin (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed EBITDA Margin for 4 consecutive years, with 10.29% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 19001.0% to 10.29% in Q4 2025 year-over-year; TTM through Dec 2025 was 91.36%, a 41082.0% increase, with the full-year FY2025 number at 91.36%, up 41082.0% from a year prior.
  • EBITDA Margin was 10.29% for Q4 2025 at Phathom Pharmaceuticals, up from 30.85% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1373.9% in Q1 2022 to a low of 10245.6% in Q4 2023.
  • A 4-year average of 995.67% and a median of 151.69% in 2025 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: crashed -1073135bps in 2023, then surged 1004530bps in 2024.
  • Phathom Pharmaceuticals' EBITDA Margin stood at 485.75% in 2022, then plummeted by -2209bps to 10245.6% in 2023, then soared by 98bps to 200.3% in 2024, then surged by 95bps to 10.29% in 2025.
  • Per Business Quant, the three most recent readings for PHAT's EBITDA Margin are 10.29% (Q4 2025), 30.85% (Q3 2025), and 151.69% (Q2 2025).